Document is current
Any future updates will be listed below
-
Authors
Dreger, Peter https://orcid.org/0000-0002-7429-8570
Ahmed, Sairah https://orcid.org/0000-0001-7302-8299
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Dietrich, Sascha
Fenske, Timothy S.
Ghosh, Nilanjan
Hermine, Olivier
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
- License Information
-
More Information
Article History
Received: 25 February 2025
Revised: 1 April 2025
Accepted: 8 April 2025
First Online: 14 April 2025
Competing interests
: PD: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. PD is current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). SA: Research support to institutions for clinical trials from Nektar, Merck, Xencor, Chimagen and Genmab, KITE/Gilead, Janssen, Caribou. Consultant for ADC therapeutics, KITE/Gilead, Genmab and BMS. SD: Roche: Advisory board; Kite/Gilead: Advisory board. TS Fenske: Consulting: AbbVie, Adaptive Biotechnologies, Ipsen, Ono Pharmaceuticals. Speaking: AstraZeneca, Beigene, SeaGen. NG: Consulting/Advisory: AbbVie, AstraZeneca, Beigene, BMS, Kite pharma, Genentech/Roche, Incyte, Janssen, ADC Therapeutics, Galapagos, Ascentage Pharma. Research funding: Genentech/Roche, AstraZeneca, AbbVie, Pepromene, Incyte, BMS. OH: Research support BMS, Blueprint, Consultant AB Science, Inatherys. KiTE/Gilead, AstraZeneca. MH: Research Support/Funding: ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, BMS, Kite, Genmab, CRISPR, Allovir, Caribou, Autolus, Forte Biosciences, Byondis, Daiichi Sankyo. Speaker’s Bureau: AstraZeneca, ADC Therapeutics, BeiGene, Kite, Sobi. AB has no COIs.
